Rectal or Anal Cancer
Conditions
Keywords
High-Dose-Rate Brachytherapy, oral capecitabine, infusional 5-FU, Questionnaires, 14-104
Brief summary
The purpose of this study is to see what amount of radiation is safe to give to rectal or anal cancer patients who are being treated with a procedure called brachytherapy.
Interventions
RADIATIONendorectal brachytherapy
Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
DRUGconcurrent capecitabine or 5-FU
Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only. Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.
BEHAVIORALQuestionnaires
Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus * Prior pelvic EBRT * Age \> or = to 18 years * ECOG performance status 0, 1, or 2 * At least 4 weeks from prior major surgery or radiotherapy * Have undergone Surgical, Medical and Radiation Oncology evaluations to confirm : * Eligible for infusional 5-FU or capecitabine * Will not undergo surgery for the study disease * Able to receive HDR brachytherapy ANC ≥ 1.5 cells/mm3 and PLT ≥100,000/mm3 * Adequate Renal function: Creatinine \<1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50cc/min * Adequate Hepatic functions: Bilirubin less than 1.5 mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL) * AST or ALT \<3xULN, or \<5x ULN if known liver metastases * Normal Cardiac function: * No active coronary artery disease; * No New York Heart Association class II, III or IV disease; * No arrhythmia requiring treatment * Maximum tumor length of 7 cm at time of brachytherapy treatment start
Exclusion criteria
* Women who are pregnant. * Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire treatment period and after receipt of brachytherapy. Male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapy. * Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study. * Patients on concurrent anti-cancer therapy other than that allowed in the study. * Contraindications to general anesthesia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum tolerated dose (MTD) | 1 year | will employ a standard 3+3 dose-escalation scheme. Patients will be accrued to the study in cohorts of 3. An initial cohort of 3 patients will be treated to each dose. The dose level will be escalated if none of the 3 patients exhibits any DLT within 90 days of completion of brachytherapy. Dose escalation will not take place until every patient in the prior dose cohort has been monitored for 90 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| tumor response | 3, 6, and 12 months | MRI with DCE & DWI (unless contraindicated) after brachytherapy |
Countries
United States
Outcome results
None listed